Market Size
The Global Gastric Motility Disorder Drugs Market reached US$ 54.7 billion in 2024 and is expected to reach US$ 90.41 billion by 2033, growing at a CAGR of 5.0% during the forecast period 2025-2033.
Gastric motility disorders refer to conditions that affect the normal movement of food through the gastrointestinal (GI) tract, leading to a range of symptoms such as nausea, vomiting, bloating, constipation, and abdominal pain. These disorders can arise from various causes, including nerve damage, structural abnormalities, or infections affecting the GI tract.
Common examples include gastroparesis, characterized by delayed gastric emptying, and functional dyspepsia, which involves discomfort in the upper abdomen without clear motor dysfunction. The complexity of these disorders often results in significant impacts on patients' quality of life, necessitating effective management strategies. Medications such as prokinetic agents (e.g., metoclopramide and domperidone) are commonly prescribed to enhance gastric emptying and alleviate nausea.
Executive Summary
For more details on this report – Request for Sample material
Market Dynamics: Drivers & Restraints
Increasing Prevalence of Gastric Motility Disorders
The increasing prevalence of gastric motility disorders is expected to significantly drive the gastric motility disorder drugs market. As the number of individuals with conditions such as gastroparesis and functional dyspepsia increases, the demand for effective treatments rises correspondingly. For instance, according to the report by the National Institute of Health in 2023, it was stated that functional dyspepsia is one of the most prevalent functional gastrointestinal disorders that affects over 20% of the population.
The occurrence of GI motility disorders approximates 50–80% in the critically ill patients. This growing patient population not only highlights the urgent need for new therapeutic options but also encourages pharmaceutical companies to invest in research and development, thereby expanding the market for gastric motility disorder drugs. Thus, the above factors are expected to drive the market growth during the forecast period.
Limited Drugs for Treatment
Limited drug options for treating gastric motility disorders can significantly hinder market growth. The lack of effective and diverse treatment alternatives leads to unmet patient needs, resulting in a reliance on existing medications that may have inadequate efficacy or severe side effects. Additionally, the complexity of drug development due to unclear underlying mechanisms of these disorders further restricts the introduction of new therapies, ultimately stifling market expansion and innovation in this sector.
Market Segment Analysis
The global gastric motility disorder drugs market is segmented based on drug type, disorder type, distribution channel, and region.
Drug Type:
Prokinetic agents segment is expected to dominate the global gastric motility disorder drugs market share
The prokinetic agents segment is poised to dominate the gastric motility disorder drugs market. This dominance is attributed to their effectiveness in alleviating various symptoms associated with gastroparesis by enhancing gastrointestinal motility and promoting gastric emptying. Prokinetic agents, such as metoclopramide and domperidone, are widely recognized for their ability to improve symptoms like nausea and bloating, making them essential in the management of gastric motility disorders.
With the growing demand for these drugs, companies are innovatively introducing these solutions to treat various gastric motility disorders. For instance, in September 2024, Avenacy launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP is indicated for the relief of symptoms associated with diabetic gastroparesis. Thus, the above factors are expected to hold the segment in the dominant position.
Market Geographical Analysis
North America is expected to hold a significant position in the global Gastric Motility Disorder Drugs market share
North America holds a major portion of the gastric motility disorder drugs market and is expected to dominate the market during the forecast period. This dominance is driven by several factors, including a high prevalence of gastric motility disorders, and significant investments in pharmaceutical research and development. The presence of major drug manufacturers in the region enhances innovation and access to advanced treatment options.
The region has a great regulatory framework supporting the entry of various innovative solutions. Several companies are initiating new clinical trials. For instance, in December 2023, The U.S. Food and Drug Administration (FDA) accepted the filing of Vanda Pharmaceuticals Inc.’s New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.
In April 2022, Processa Pharmaceuticals, Inc. announced that it enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. The above factors are expected to hold the region in the dominant position.
Major Global Players
The major global players in the gastric motility disorder drugs market include Pfizer Inc., Eisai Co., Ltd., Mallinckrodt, Salvus Pharma, Atmo Biosciences, AdvaCare Pharma, Avenacy, VAIKUNTH CHEMICALS PVT. LTD., Healthy Inc and Bhumi Pharmaceuticals among others.
| Metrics | Details | |
| CAGR | 5.0% | |
| Market Size Available for Years | 2022-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Drug Type | Parasympathomimetics, Prokinetic Agents, Opioid Antagonists, Antidiarrheals, Anti-Emetic Drugs, Antibiotics, Others |
| Disorder Type | Achalasia, Esophageal spasms, Heartburn, or Gastroesophageal Reflux Disease (GERD), Gastroparesis, Irritable Bowel Syndrome (IBS), Fecal incontinence, Intestinal Pseudo-obstruction, Others | |
| Distribution Channel | Hospital Pharmacies, Online Pharmacies, Retail Pharmacies | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Key Developments
- In March 2024, Renexxion Ireland Limited announced that the U.S. Food and Drug Administration (FDA) has granted clearance for their Investigational New Drug (IND) application for naronapride. This drug is intended to treat patients suffering from gastroparesis, a condition characterized by delayed gastric emptying.
- In September 2023, Aclipse Therapeutics and its subsidiary, Aclipse Two, Inc., announced the signing of an exclusive licensing agreement with Chong Kun Dang Pharmaceutical Corporation (CKD), based in Seoul, South Korea. This agreement grants Aclipse the worldwide rights (excluding South Korea, Indonesia, and Vietnam) to develop CKD's lobeglitazone for the treatment of gastroparesis and other potential indications.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Gastric Motility Disorder Drugs Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2025
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
